Selective Killing of Cancer Cells by Nonplanar Aromatic Hydrocarbon-Induced DNA Damage

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2019 Nov 16

PMID 31728285

Citations 9

Authors

Yan Zhou

Fuwei Gan

Yuanliang Zhang

Xiaozhen He

Chengshuo Shen

Huibin Qiu

Peifeng Liu

Affiliations

Soon will be listed here.

Abstract

A large number of current chemotherapeutic agents prevent the growth of tumors by inhibiting DNA synthesis of cancer cells. It has been found recently that many planar polycyclic aromatic hydrocarbons (PAHs) derivatives, previously known as carcinogenic, display anticancer activity through DNA cross-linking. However, the practical use of these PAHs is substantially limited by their low therapeutic efficiency and selectivity toward most tumors. Herein, the anticancer property of a nonplanar PAH named [4]helicenium, which exhibits highly selective cytotoxicity toward liver, lung cancer, and leukemia cells compared with normal cells, is reported. Moreover, [4]helicenium effectively inhibits tumor growth in liver cancer-bearing mice and shows little side effects in normal mice. RNA sequencing and confirmatory results demonstrate that [4]helicenium induces more DNA damage in tumor cells than in normal cells, resulting in tumor cell cycle arrest and apoptosis increment. This study reveals an unexpected role and molecular mechanism for PAHs in selectively killing tumor cells and provides an effective strategy for precision cancer therapies.

Citing Articles

Catalytic kinetic resolution of helical polycyclic phenols via an organocatalyzed enantioselective dearomative amination reaction.

Chu A, Zhu B, Zhang X, Zhu H, Zhang J, Liu X Sci Adv. 2024; 10(47):eadr1628.

PMID: 39576850 PMC: 11584004. DOI: 10.1126/sciadv.adr1628.

Enantioselective synthesis of [4]helicenes by organocatalyzed intermolecular C-H amination.

Liu X, Zhu B, Zhang X, Zhu H, Zhang J, Chu A Nat Commun. 2024; 15(1):732.

PMID: 38272928 PMC: 10810882. DOI: 10.1038/s41467-024-45049-w.

The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors.

Wang G, Cao J, Gui M, Huang P, Zhang L, Qi R J Exp Clin Cancer Res. 2023; 42(1):284.

PMID: 37891570 PMC: 10604416. DOI: 10.1186/s13046-023-02848-1.

Recent Advances in Electrochemical Biosensors for Monitoring Animal Cell Function and Viability.

Koo K, Kim C, Ju F, Kim H, Kim C, Kim T Biosensors (Basel). 2022; 12(12).

PMID: 36551129 PMC: 9775431. DOI: 10.3390/bios12121162.

[5]-Helistatins: Tubulin-Binding Helicenes with Antimitotic Activity.

Rushworth J, Thawani A, Fajardo-Ruiz E, Meiring J, Heise C, White A JACS Au. 2022; 2(11):2561-2570.

PMID: 36465552 PMC: 9709948. DOI: 10.1021/jacsau.2c00435.

References

Gu X, Li H, Shan B, Liu Z, Miao Q . Synthesis, Structure, and Properties of Tetrabenzo[7]circulene. Org Lett. 2017; 19(9):2246-2249. DOI: 10.1021/acs.orglett.7b00714. View

Wunz T, Craven M, Karol M, Hill G, Remers W . DNA binding by antitumor anthracene derivatives. J Med Chem. 1990; 33(6):1549-53. DOI: 10.1021/jm00168a005. View

Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B . Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017; 17(5):286-301. DOI: 10.1038/nrc.2017.17. View

Perry P, Gowan S, Reszka A, Polucci P, Jenkins T, Kelland L . 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. J Med Chem. 1998; 41(17):3253-60. DOI: 10.1021/jm9801105. View

Oun R, Moussa Y, Wheate N . The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018; 47(19):6645-6653. DOI: 10.1039/c8dt00838h. View

Perni R, Wentland M, Huang J, Powles R, Aldous S, Klingbeil K . Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. J Med Chem. 1998; 41(19):3645-54. DOI: 10.1021/jm9708083. View

Moorthy B, Chu C, Carlin D . Polycyclic aromatic hydrocarbons: from metabolism to lung cancer. Toxicol Sci. 2015; 145(1):5-15. PMC: 4408964. DOI: 10.1093/toxsci/kfv040. View

McNerney M, Godley L, Le Beau M . Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017; 17(9):513-527. PMC: 5946699. DOI: 10.1038/nrc.2017.60. View

Scheer M, Schneider K, Finnigan R, Maloney E, Wells M, Clemens D . The Involvement of Acetaldehyde in Ethanol-Induced Cell Cycle Impairment. Biomolecules. 2016; 6(2). PMC: 4919912. DOI: 10.3390/biom6020017. View

10.

Horn L, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M . First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. View

11.

Boffetta P, Jourenkova N, Gustavsson P . Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control. 1997; 8(3):444-72. DOI: 10.1023/a:1018465507029. View

12.

Nestoros E, Stuparu M . Corannulene: a molecular bowl of carbon with multifaceted properties and diverse applications. Chem Commun (Camb). 2018; 54(50):6503-6519. DOI: 10.1039/c8cc02179a. View

13.

Venitt S, Agbandje M, Jenkins T, Neidle S . Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity. J Med Chem. 1998; 41(19):3748-52. DOI: 10.1021/jm980167r. View

14.

Wang A, Kim T, Wagner J, Conti B, Lach F, Huang A . A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. Mol Cell. 2015; 59(3):478-90. PMC: 4529964. DOI: 10.1016/j.molcel.2015.07.009. View

15.

Valente L, Gray D, Michalak E, Pinon-Hofbauer J, Egle A, Scott C . p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013; 3(5):1339-45. DOI: 10.1016/j.celrep.2013.04.012. View

16.

Zhou Y, Gan F, Zhang Y, He X, Shen C, Qiu H . Selective Killing of Cancer Cells by Nonplanar Aromatic Hydrocarbon-Induced DNA Damage. Adv Sci (Weinh). 2019; 6(21):1901341. PMC: 6839640. DOI: 10.1002/advs.201901341. View

17.

Dorr R, Liddil J, Sami S, Remers W, Hersh E, Alberts D . Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anticancer Drugs. 2001; 12(3):213-20. DOI: 10.1097/00001813-200103000-00007. View

18.

Lown J . Anthracycline and anthraquinone anticancer agents: current status and recent developments. Pharmacol Ther. 1993; 60(2):185-214. DOI: 10.1016/0163-7258(93)90006-y. View

19.

Hardie M, Kava H, Murray V . Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy. Curr Pharm Des. 2016; 22(44):6645-6664. DOI: 10.2174/1381612822666160831101529. View

20.

Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn M, Timmers C, Hejna J . Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001; 7(2):249-62. DOI: 10.1016/s1097-2765(01)00173-3. View